Literature DB >> 3390792

Cancer-associated elevation of alpha(1----3)-L-fucosyltransferase activity in human serum.

S Yazawa1, R Madiyalakan, H Izawa, T Asao, K Furukawa, K L Matta.   

Abstract

GDP-fucose:N-acetylglucosaminide alpha(1----3)-L-fucosyltransferase activity was measured in sera of patients with various cancers using a synthetic substrate, N-acetyl-2'-O-methyllactosamine, as an acceptor. One hundred twenty-four of the 169 patients showed significantly high levels of the enzyme activity when compared to healthy controls, irrespective of the location of their tumor. However, enzyme levels were in the normal range in patients with non-neoplastic diseases, such as infectious disease, liver disease, and other inflammatory problems as well as in leukemic patients. The chromatofocusing profile of the enzyme using PBE-94 gel over a pH gradient from pH 6.0 to 4.0 demonstrated that the level of enzyme eluted at pH 5.4 was markedly elevated in the sera of stomach and ovarian cancer patients. A correlation was established between alpha(1----3)-L-fucosyltransferase activity and the presence of malignancy which may be used to evaluate the utility of the enzyme as a tumor marker.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3390792     DOI: 10.1002/1097-0142(19880801)62:3<516::aid-cncr2820620313>3.0.co;2-4

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

1.  Tumor-related elevation of serum (alpha 1----3)-L-fucosyltransferase activity in gastric cancer.

Authors:  S Yazawa; T Asao; Y Nagamachi; S A Abbas; K L Matta
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

2.  A new method for assaying adhesion of cancer cells to the greater omentum and its application for evaluating anti-adhesion activities of chemically synthesized oligosaccharides.

Authors:  A Okamura; S Yazawa; T Nishimura; S Tanaka; I Takai; S Kudo; T Asao; H Kuwano; K L Matta; S Akamatsu; N Kochibe
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

3.  Tumor cells as the origin of elevated serum alpha1,3fucosyltransferase in association with malignancy.

Authors:  T Asao; H Kuwano; J Nakamura; A Okamura; E G Berger; K L Matta; S Yazawa
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Associated expression of α2,3sialylated type 2 chain structures with lymph node metastasis in distal colorectal cancer.

Authors:  Takaharu Fukasawa; Takayuki Asao; Hayato Yamauchi; Munenori Ide; Yuichi Tabe; Takaaki Fujii; Satoru Yamaguchi; Soichi Tsutsumi; Shin Yazawa; Hiroyuki Kuwano
Journal:  Surg Today       Date:  2012-03-08       Impact factor: 2.549

5.  A novel method for determination of alpha1,6fucosyltransferase activity using a reducing oligosaccharide from egg yolk as a specific acceptor.

Authors:  S Yazawa; N Kochibe; T Nishimura; C Shima; I Takai; M Adachi; T Asao; T Hada; Y Enoki; L R Juneja
Journal:  Glycoconj J       Date:  1998-09       Impact factor: 2.916

6.  Elevation of an alpha(1,3)fucosyltransferase activity correlated with apoptosis in the human colon adenocarcinoma cell line, HT-29.

Authors:  S Akamatsu; S Yazawa; K Zenita; H Matsumoto; T Tachikawa; R Kannagi
Journal:  Glycoconj J       Date:  1996-12       Impact factor: 2.916

7.  The usefulness of anti-fucosylated antigen antibody YB-2 for diagnosis of hepatocellular carcinoma.

Authors:  J Nakamura; S Yazawa; T Hada; T Asao; H Naitoh; S Takenoshita; M Kosaka; S Akamatsu; T Tachikawa; Y Nagamachi
Journal:  Glycoconj J       Date:  1997-01       Impact factor: 2.916

8.  A high throughput method for identifying personalized tumor-associated antigens.

Authors:  Yurij Ionov
Journal:  Oncotarget       Date:  2010-06

9.  Transcriptional regulation of the fucosyltransferase VI gene in hepatocellular carcinoma cells.

Authors:  Koji Higai; Noriko Miyazaki; Yutaro Azuma; Kojiro Matsumoto
Journal:  Glycoconj J       Date:  2008-02-15       Impact factor: 2.916

10.  Increased plasma alpha (1 --> 3)-L-fucosyltransferase activities in patients with hepatocellular carcinoma.

Authors:  T Hada; K Fukui; M Ohno; S Akamatsu; S Yazawa; K Enomoto; K Yamaguchi; Y Matsuda; Y Amuro; N Yamanaka
Journal:  Glycoconj J       Date:  1995-10       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.